Stenzl - Figure 26

Overall Survival According to Molecular Subtype

FIG. 26:  Importantly, these different tumors fare differently with respect to response to neoadjuvant chemotherapy when the TURB specimen is compared with the cystectomy specimen.[19]  For example, in the UNC classification,[4] basal tumors respond well to neoadjuvant chemotherapy, as well as cluster III tumors in the TCGA classification.[2]  But when infiltrative and Uro B tumors are classified according to the Lund classification,[3] there is a significant change between the primary TURB and the cystectomy specimen if neoadjuvant chemotherapy was applied.

References

[2]

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014:507:315−22  nature.com/doifinder/10.1038/nature12965

[3]

Sjödahl G, Lauss M, Lövgren K, Chebil G, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377−86  https://doi.org/10.1158/1078-0432.CCR-12-0077-T

[4]

Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;25:3110–5  https://doi.org/10.1073/pnas.1318376111

[19]

Seiler R, Ashab HA, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. Published online April 5, 2017  http://dx.doi.org/10.1016/j.eururo.2017.03.030